Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug

International Journal of Pharmaceutics

Volumn 299, Issue 1-2, 2005, Pages 84-91

  Kranz, H ^a   Le Brun, V ^a   Wagner, T ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Controlled release; Fumaric acid; Mini matrix tablets; pH Independence; Weakly basic drug

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; BUFFER; CALCIUM PHOSPHATE; CHEMOKINE RECEPTOR ANTAGONIST; FUMARIC ACID; KOLLIDON SR; LACTOSE; POLYVINYL ACETATE; POVIDONE; SOLVENT; STARCH;

ALKALINITY; ARTICLE; DISSOLUTION; DRUG DECOMPOSITION; DRUG GRANULE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; HUMIDITY; MATRIX TABLET; PARTICULATE MATTER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REPRODUCIBILITY; STOMACH PH; SUSTAINED DRUG RELEASE; TABLET COMPRESSION; TABLET FORMULATION;

CALCIUM PHOSPHATES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; FUMARATES; HYDROGEN-ION CONCENTRATION; LACTOSE; PHENYLUREA COMPOUNDS; PIPERIDINES; POLYVINYLS; POVIDONE; RECEPTORS, CHEMOKINE; SOLUBILITY; STARCH; TABLETS;

EID: 21844451622     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.04.026     Document Type: Article

References (16)

1. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliv. Rev. 50 2001 41 67
2. BASF AG, 1999. Technical information for Kollidon SR. Ludwigshafen, Germany.
3. Bauman, J.G., Buckman, B.O., Ghannam, A.F., Hesselgesser, J.E., Horuk, R., Islam, I., Liang, M., May, K.B., Monahan, S.D., Morissey, M.M., Ng, H.P., Wei, G.P., Xu, W., Zheng, W., 1998. Piperazine derivatives and their use as anti-inflammatory agents. WO 98/56771.
4. ® MAE 30 DP Eur. J. Pharm. Biopharm. 58 2004 45 49
5. C. Doherty, and P. York Microenvironmental pH control of drug dissolution Int. J. Pharm. 50 1998 223 232
6. E. Draganoiu, M. Andheria, and A. Sakr Evaluation of the new polyvinylacetate/povidone excipient for matrix sustained release dosage forms Pharm. Ind. 63 2001 624 629
7. R. Espinoza, E. Hong, and L. Villafuerte Influence of admixed citric acid in the release profile of pelanserin hydrochloride from HPMC matrix tablets Int. J. Pharm. 201 2000 165 173
8. K.E. Gabr Effect of organic acids on the release patterns of weakly basic drugs from inert sustained release matrix tablets Eur. J. Pharm. Biopharm. 38 1992 199 202
9. K. Kolter, R. Bodmeier, and A. Dashevsky Kombination von Polyvinylacetat mit wasserunlöslichen, säureunlöslichen oder alkaliunlö sliehen Polymeren zur Herstellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität Deutsche Offenlegungsschrift DE 102 11 289 A 1 2002
10. Merck & Co. Inc., 1996. Merck Index, vol. XII. Whitehouse Station, NJ.
11. S. Narisawa, M. Nagata, Y. Hirakawa, M. Kobayashi, and H. Yoshino An organic acid-induced sigmoidal release system for oral controlled release preparations. 3. Elucidation of the anomalous drug release behavior through osmotic pumping mechanism Int. J. Pharm. 148 1997 85 91
12. Oren, P.L., Seidler, W.M.K., 1990. Sustained Release Matrix. US Patent No. 4,968,508.
13. A.C. Shah Design of oral sustained release drug delivery systems A. Yacobi E. Halperin-Walega Oral Sustained Release Formulation Design and Evaluation 1988 Pergamon Press New York 35 56
14. Z.J. Shao, M.I. Farooqi, S. Diaz, A.K. Krishna, and N.A. Muhammad Effects of formulation variables and post compression curing on drug release from a new sustained release matrix material: polyvinylacetate/povidone Pharm. Dev. Tech. 6 2001 247 254
15. A. Streubel, J. Siepmann, A. Dashevsky, and R. Bodmeier pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets J. Control. Release 67 2000 101 110
16. K. Thoma, and I. Ziegler pH-independent release of fenoldopam from pellets with insoluble film coats Eur. J. Pharm. Biopharm. 46 1998 105 113